HZNP - Amgen's Horizon Acquisition Offers Multiple Advantages: Tax Breaks Shield From Drug Pricing Negotiations | Benzinga
On Friday, the U.S. Federal Trade Commission (FTC) gave a green light to Amgen Inc's (NASDAQ: AMGN) acquisition of Horizon Therapeutics Plc (NASDAQ: HZNP), which contradicts its earlier commitment to tighter antitrust checks.
This decision potentially provides Amgen with a portfolio of drugs shielded from fresh pricing negotiations and possible tax relief benefits.
This move hints at the FTC's hesitation, doubting a court would back its view of Amgen's potential undue advantage in "bundling" drug negotiations with insurance firms.
Abiel Garcia, a former deputy attorney general specializing in antitrust matters in ...